Protagenic Sells Subsidiary
Ticker: PTIXW · Form: 8-K · Filed: Sep 18, 2024 · CIK: 1022899
| Field | Detail |
|---|---|
| Company | Protagenic Therapeutics, Inc.\New (PTIXW) |
| Form Type | 8-K |
| Filed Date | Sep 18, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: divestiture, strategic-shift, subsidiary-sale
Related Tickers: PTIX
TL;DR
Protagenic selling off a subsidiary to focus on core biz. Deal expected Q4.
AI Summary
Protagenic Therapeutics, Inc. announced on September 17, 2024, that it has entered into a definitive agreement to sell its wholly-owned subsidiary, Protagenic Biologics, Inc., to an unaffiliated third party. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions. This sale is part of the company's strategic plan to focus on its core business operations.
Why It Matters
This divestiture signals a strategic shift for Protagenic Therapeutics, potentially allowing them to concentrate resources on their primary business objectives and streamline operations.
Risk Assessment
Risk Level: medium — The sale of a subsidiary can introduce uncertainty regarding future revenue streams and operational focus, impacting the company's strategic direction.
Key Players & Entities
- Protagenic Therapeutics, Inc. (company) — Filer
- Protagenic Biologics, Inc. (company) — Subsidiary being sold
- September 17, 2024 (date) — Date of definitive agreement
- fourth quarter of 2024 (date) — Expected closing period
FAQ
What is the name of the subsidiary being sold?
The subsidiary being sold is Protagenic Biologics, Inc.
When was the definitive agreement for the sale signed?
The definitive agreement was signed on September 17, 2024.
When is the sale of the subsidiary expected to close?
The sale is expected to close in the fourth quarter of 2024.
What is the reason for selling the subsidiary?
The sale is part of the company's strategic plan to focus on its core business operations.
Are there any conditions for the closing of the sale?
Yes, the sale is subject to customary closing conditions.
Filing Stats: 341 words · 1 min read · ~1 pages · Grade level 11.9 · Accepted 2024-09-17 21:54:15
Filing Documents
- form8-k.htm (8-K) — 42KB
- 0001493152-24-036925.txt ( ) — 257KB
- ptix-20240917.xsd (EX-101.SCH) — 4KB
- ptix-20240917_def.xml (EX-101.DEF) — 29KB
- ptix-20240917_lab.xml (EX-101.LAB) — 36KB
- ptix-20240917_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROTAGENIC THERAPEUTICS, INC. Date: September 17, 2024 By: /s/ Alexander K. Arrow Name: Alexander K. Arrow Title: Chief Financial Officer 3